-
Detailed Analysis Download Full Stock Report Add to Watchlist
Values as of: 2022-05-16
Last Closing Price
USD 4.03Change
0.00 (0.00)%Market Cap
USD 0.10BVolume
0.27MYahoo Analyst Target
USD 3.00 (-25.56%)Avg Analyst Target
N/A
N/A
Verdict
Values as of: 2022-05-16
Last Closing Price
USD 4.03Change
0.00 (0.00)%Market Cap
USD 0.10BVolume
0.27MYahoo Analyst Target
USD 3.00 (-25.56%)Avg Analyst Target
N/AN/A
Verdict
Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aq ...Read More
Company Website : http://www.aqxpharma.com
Address : 887 Great Northern Way, Suite 450 V5T 4T5,Vancouver,CAN
Employees : 8
Fiscal Year End : December
Currency: USD
Country : USA
Beta : 0.92
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | -72.32% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -72.32% | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -5.96% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -5.96% | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 49.61% | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | -12.01% | N/A | N/A | N/A | N/A | ||
Market Capitalization | 0.10B | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | -3.28 | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | -26.25% | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Dividend Yield | N/A | N/A | N/A | N/A | N/A | ||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | 0.92 | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
No discussions yet
User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
The company had negative total cash flow in the most recent four quarters.